Should you buy Hims & Hers Health stock now?
The technical signal for Hims & Hers Health is currently NEUTRAL. Hims & Hers Health trades at $30.28 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is negative (bearish trend) at -0.692 with falling momentum (signal: -0.582); RSI is at 51.0 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $29.23 is 3.5% below the current price. This is a technical observation based on current data, not investment advice.
What is the price target for Hims & Hers Health stock?
The average analyst price target for Hims & Hers Health is $29.23. The current price is $30.28, which gives a downside of 3.5%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $26.31 and $32.15.
Is Hims & Hers Health a dividend stock?
No, Hims & Hers Health does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Hims & Hers Health stock?
Hims & Hers Health is rated as a stock with extreme risk. the annual standard deviation is 91.5%, which classifies the stock as extreme risk.
Is Hims & Hers Health overvalued?
Hims & Hers Health is considered fairly valued – the price is close to the analyst price target. Hims & Hers Health has the following valuation ratios: a P/S ratio of 3.1, a P/B ratio of 14.4. The stock trades close to the analyst price target and is considered fairly valued.
Is Hims & Hers Health overbought?
No, Hims & Hers Health is not overbought. RSI is at 51.0 (neutral zone). The technical indicators show: RSI is at 51.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.6% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Hims & Hers Health earnings report?
Hims & Hers Health reports its next earnings on August 10, 2026. The stock currently trades at $30.28.
Is Hims & Hers Health shorted?
Yes, Hims & Hers Health is shorted with 31.9% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Hims & Hers Health stock?
No, insiders are not buying Hims & Hers Health shares – they are net sellers. Over the last 3 months, insiders have made 1 purchases and 17 sales. On a net basis, 23,808,741 $ worth of shares were sold. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 24,681,195 $ sold. Active sellers include Okupe Oluyemi, Carroll Patrick Harrison, Elshenawy Mohamed and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Hims & Hers Health a good stock?
Based on our total score, Hims & Hers Health is rated as a poor stock with a total score of 21 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 15/100, Quality: 29/100, Momentum: 19/100. In addition: technical signal: Hold. Whether Hims & Hers Health is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Hims & Hers Health stock?
The outlook for Hims & Hers Health based on current data: the average analyst price target is $29.23 (-3.5%); the next earnings report is due on 8/10/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Hims & Hers Health stock falling?
Hims & Hers Health is falling right now. The technical indicators show: the price is 4.6% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 31.9% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Hims & Hers Health go?
The average analyst price target for Hims & Hers Health is $29.23, which is 3.5% below the current price of $30.28. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Hims & Hers Health fall?
We lack enough history to give a specific floor for Hims & Hers Health. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Hims & Hers Health do?
Hims & Hers Health, Inc. driver en digital sundhedsplatform, hvor folk kan tale med læger online. De tjener primært penge på abonnementer, hvor kunder får tilsendt receptpligtig medicin direkte. Virksomheden tilbyder en bred vifte af sundheds- og velværeprodukter via deres hje... The company belongs to the Defensivt forbrug sector, more specifically the Drug Manufacturers - Specialty & Generic industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Hims & Hers Health as an investment.
Did Hims & Hers Health raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Hims & Hers Health. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Hims & Hers Health making money or losing money?
No, Hims & Hers Health is currently not making money — the company is losing money with a negative profit margin of -0.6%, a small loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Hims & Hers Health go bankrupt?
The bankruptcy risk of Hims & Hers Health is rated as elevated. Altman Z2 (a model for assessing financial distress) is 1.08 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 48% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Hims & Hers Health have a lot of debt?
No, Hims & Hers Health has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 48%. For the defensivt forbrug sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
